Earnings summaries and quarterly performance for Mirum Pharmaceuticals.
Executive leadership at Mirum Pharmaceuticals.
Board of directors at Mirum Pharmaceuticals.
Research analysts who have asked questions during Mirum Pharmaceuticals earnings calls.
Ryan Deschner
Raymond James Financial
6 questions for MIRM
Also covers: APLS, ARDX, ARSP +7 more
DL
David Lebowitz
Citigroup Inc.
4 questions for MIRM
Also covers: ALNY, ARWR, ASND +11 more
Gavin Clark-Gartner
Evercore ISI
4 questions for MIRM
Also covers: ACRS, ARGX, ASND +12 more
JF
Jessica Fye
JPMorgan Chase & Co.
4 questions for MIRM
Also covers: ALKS, ALNY, AMRN +23 more
Brian Skorney
Robert W. Baird & Co.
3 questions for MIRM
Also covers: ABUS, BIIB, CRNX +8 more
JW
Jon Wolleben
Citizen JMP
3 questions for MIRM
Also covers: BCRX, CLSD, CRNX +4 more
Joseph Thome
TD Cowen
3 questions for MIRM
Also covers: ALKS, AMLX, ARDX +12 more
CW
Charles Wallace
HCW
2 questions for MIRM
Also covers: CGEN, DCTH, ECOR +1 more
James Condulis
Stifel
2 questions for MIRM
Also covers: CYTK, FULC, SLNO
JK
Joe Kim
Water Tower Research
2 questions for MIRM
Also covers: AWH
JW
Jonathan Wolleben
JMP Securities, a Citizens Company
2 questions for MIRM
Also covers: ALT, BCRX, CLSD +6 more
MU
Michael Ulz
Morgan Stanley
2 questions for MIRM
Also covers: ALNY, ARWR, FATE +8 more
R
Rohit
Morgan Stanley
2 questions for MIRM
R
Ryan
B. Riley
2 questions for MIRM
Also covers: ARLO, AVNT, AXTA +4 more
Ryan Mcelroy
Leerink Partners
2 questions for MIRM
Also covers: BBIO, RGNX
Abdullah
J.P. Morgan
1 question for MIRM
Catherine Okoukoni
Citizens JMP
1 question for MIRM
Also covers: ALT, CRNX, KALV +2 more
DG
Dae Gon Ha
Stifel
1 question for MIRM
Also covers: ABEO, BEAM, CRBP +10 more
GC
Gavin Clark-Gardner
Evercore
1 question for MIRM
JS
Josh Schimmer
Cantor Fitzgerald
1 question for MIRM
Also covers: BBIO, BYSI, CRNX +5 more
JS
Joshua Schimmer
Evercore ISI
1 question for MIRM
Also covers: KRYS, NBIX, SPRY
M
Mark
Stifel
1 question for MIRM
Also covers: NTLA, SLNO
Rohit Bhasin
Morgan Stanley
1 question for MIRM
Also covers: GUTS, VKTX
Selena Zhang
Morgan Stanley
1 question for MIRM
SR
Swayampakula Ramakanth
H.C. Wainwright & Co.
1 question for MIRM
Also covers: ABSI, BSEM, CGEN +24 more
TY
Thomas Yip
H.C. Wainwright & Co.
1 question for MIRM
Also covers: ABUS, ARDX, ENTA +6 more
Timur Ivannikov
Raymond James
1 question for MIRM
Also covers: APLS, GLMD, IFRX +1 more
Recent press releases and 8-K filings for MIRM.
Mirum Pharmaceuticals Announces Q4 and Full Year 2025 Results and 2026 Guidance
MIRM
Earnings
Guidance Update
Product Launch
2 days ago
Mirum Pharmaceuticals Reports Strong 2025 Financial Results and Provides 2026 Guidance with Key Pipeline Milestones
MIRM
Earnings
Guidance Update
New Projects/Investments
- Mirum Pharmaceuticals reported $521 million in net product sales for the full year 2025, surpassing its guidance and marking 55% year-over-year growth.
- For 2026, the company projects net product sales of $630 million to $650 million, primarily driven by LIVMARLI, and achieved positive cash flow from operations in 2025, ending the year with $391 million in cash equivalents.
- The pipeline was significantly expanded with the addition of the Phase III brelovitug program for chronic hepatitis delta virus, contributing to four potentially registrational clinical readouts expected over the next 18 months.
- Upcoming key data readouts in the second quarter of 2026 include top-line data from the volixibat VISTA study in PSC and interim results from the AZURE-1 study of brelovitug in hepatitis delta.
2 days ago
Mirum Pharmaceuticals Announces Q4 and Full Year 2025 Financial Results and 2026 Outlook
MIRM
Earnings
Guidance Update
New Projects/Investments
- Mirum Pharmaceuticals reported total net product sales of $521 million for the full year 2025, representing 55% year-over-year growth, and $149 million for Q4 2025.
- The company provided 2026 net product sales guidance of $630 million to $650 million.
- Mirum ended 2025 with $391 million in cash equivalents and achieved positive cash flow from operations for the year.
- The pipeline anticipates four potentially registrational clinical readouts over the next 18 months, including top-line data from the volixibat VISTA study in PSC and interim results from the AZURE-1 study of brelovitug in hepatitis delta, both expected in Q2 2026.
- R&D expense is projected to increase by approximately $150 million in 2026, primarily for the brelovitug program, with a return to positive cash flow expected in 2027.
2 days ago
Mirum Pharmaceuticals Reports Q4 and Full-Year 2025 Results and Provides 2026 Guidance
MIRM
Earnings
Guidance Update
New Projects/Investments
- Mirum Pharmaceuticals reported total net product sales of $521.3 million for the full year ended December 31, 2025, and $148.9 million for the three months ended December 31, 2025.
- The company expects global net product sales of $630 million to $650 million for 2026.
- Mirum reported a net loss of $23.363 million for the full year ended December 31, 2025, with a net loss per share of $(0.47).
- Key pipeline milestones for 2026 include topline data for the Volixibat VISTAS study in PSC in Q2 2026, LIVMARLI EXPAND study in Q4 2026, and Brelovitug AZURE-1 and AZURE-4 studies in HDV in H2 2026.
- As of December 31, 2025, unrestricted cash, cash equivalents, and investments totaled $391.4 million.
2 days ago
Mirum Pharmaceuticals Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance
MIRM
Earnings
Guidance Update
New Projects/Investments
- Mirum Pharmaceuticals reported total net product sales of $521.3 million for the full year ended December 31, 2025, an increase from $336.4 million in 2024.
- The company expects global net product sales of $630 million to $650 million for 2026.
- Key pipeline milestones include topline data expected in Q2 2026 for the Volixibat VISTAS study in PSC, topline data in Q4 2026 for the LIVMARLI EXPAND study, and topline data in H2 2026 for the Brelovitug AZURE-1 and AZURE-4 studies in HDV.
- As of December 31, 2025, Mirum Pharmaceuticals had unrestricted cash, cash equivalents and investments of $391.4 million.
2 days ago
Mirum Pharmaceuticals Provides 2026 Sales Guidance and Pipeline Updates
MIRM
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Mirum Pharmaceuticals projects 2026 Net Product Sales of $630-$650M, following a 91% CAGR in net product sales from $75M in 2022 to $521M in 2025.
- The company anticipates a peak revenue potential exceeding $4 billion for its portfolio, with key products such as LIVMARLI, Volixibat, and MRM-3379 each having over $1 billion potential.
- Significant pipeline milestones are expected, including four potentially registrational topline readouts within the next 18 months, such as VISTAS (PSC) in Q2 2026 and AZURE-1 & 4 (HDV) in H2 2026.
- Mirum aims to achieve cash flow positive status in 2027 and reported a cash balance of $391M.
3 days ago
Mirum Pharmaceuticals announces Health Canada approval for LIVMARLI® tablets and new indication
MIRM
Product Launch
- Health Canada has approved Mirum Pharmaceuticals' LIVMARLI® (maralixibat) tablets for the treatment of cholestatic pruritus in patients with Alagille syndrome.
- This new tablet formulation provides an additional option to the already approved oral solution in Canada, specifically for patients weighing at least 22 kg who are able to swallow tablets.
- Mirum Pharmaceuticals also announced that Health Canada has approved LIVMARLI® (both oral solution and tablets) for the treatment of cholestatic pruritus in patients aged 12 months or older with Progressive Familial Intrahepatic Cholestasis (PFIC).
Feb 5, 2026, 1:52 PM
Mirum Pharmaceuticals Announces Health Canada Authorization for LIVMARLI Tablet Formulation
MIRM
Product Launch
- Mirum Pharmaceuticals announced on February 5, 2026, that Health Canada has authorized the tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).
- This new tablet formulation complements the existing 9.5 mg/ml oral solution, providing an additional dosing option for ALGS patients weighing 22 kg or more who are able to swallow tablets, enhancing dosing flexibility and continuity of care.
- LIVMARLI was previously authorized in Canada as an oral solution for the treatment of cholestatic pruritus in ALGS patients aged 12 months or older.
- On the same day, Mirum also announced Health Canada's authorization of LIVMARLI® for the treatment of cholestatic pruritus in patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC), including both the 19 mg/mL oral solution and tablet formulations.
Feb 5, 2026, 1:51 PM
Mirum Pharmaceuticals Receives Health Canada Authorization for LIVMARLI in PFIC
MIRM
Product Launch
New Projects/Investments
- Mirum Pharmaceuticals announced that Health Canada has authorized LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients aged 12 months or older with progressive familial intrahepatic cholestasis (PFIC).
- The authorization includes both oral solution and tablet formulations, offering flexible dosing options for patients.
- This approval is supported by data from the Phase 3 MARCH study, which demonstrated a highly statistically significant reduction in pruritus severity in patients with PFIC.
Feb 5, 2026, 1:00 PM
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics
MIRM
M&A
New Projects/Investments
Product Launch
- Mirum Pharmaceuticals, Inc. completed the acquisition of Bluejay Therapeutics on January 23, 2026.
- The acquisition grants Mirum worldwide rights to brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus (HDV), which has received FDA Breakthrough Therapy and European Medicines Agency PRIME designations.
- Topline Phase 3 results for brelovitug are anticipated in the second half of 2026, with a potential Biologics License Application (BLA) submission and launch in 2027.
- The transaction included upfront consideration of up to $280.8 million in cash and 4,673,597 shares of common stock, along with potential milestone payments of up to $200 million in cash.
- Concurrently, Mirum completed private placement financings, raising approximately $268.5 million in gross proceeds to support clinical development and commercial activities for brelovitug.
Jan 26, 2026, 9:10 PM
Quarterly earnings call transcripts for Mirum Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more